Top Articles

Will the Senate be able to come up with a workable set of US Patent System rules to

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

streamline the bottleneck in the United States Patent Office? Will these new rules

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

help the technology industry move forward or will the laws simply be more of the s

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

ame and further stifle innovation in this country. And even if we have new laws in

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

our nation, how can we insure that other nations will follow suit and honor these p

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

atents once filed?

Of course the Senate is on Vacation, which is just as well as t

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

hey are usually said to be out to lunch these days on Patent Issues and the need fo

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

a complete overhaul of the US Patent System. Senators Hatch and Leahy put forth a

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

nearly 50-page bill to help streamline the system, but is this more legislation and

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

regulation on top of more manure?

Some say that this bill actually has some very

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

good stuff in it this go around. Will this Patent Reform Act of 2006 solve the ills

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

of the US Patent Office? Only time will tell.

The First to File scenarios being p

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

ut forth would be more inline with other countries and the venue issues for patent

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

disputes might also help things in the market place. The Coalition for Patent Fairn

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

ss likes the bill and God knows we need to do something here, as this backlog is ki

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

lling American Technology right now.

This is certainly a step in the right directi

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

on, as we are our own worst enemies with our litigious nature, patent backlogs and

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

patchwork of patent rules. Our economy is better served by a better patent system a

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

nd more fair rules and regulations. Of course all these things must be worked out a

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

nd some day we need to stop this patent piracy issue too. Consider all this in 2006

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.toparticles.org.ua/article/130752/toparticles-New-Patent-Bill-is-It-Worthy-of-Its-PR.html">New Patent Bill; is It Worthy of Its PR?</a>

BB link (for phorums):
[url=http://www.toparticles.org.ua/article/130752/toparticles-New-Patent-Bill-is-It-Worthy-of-Its-PR.html]New Patent Bill; is It Worthy of Its PR?[/url]

Teaching yourself how to use your QuickBooks file is a money-saving way to find out what you need to know. You no longer need to be afraid of what a certain transaction will do, because you can find out right now by experimenting in a sample QuickBooks file. Here are step by step instructions for using this valuable tool.

Looking for ways to boost your CRM through ROIs? Let us discuss about some ways to achieve your goals. Whatever CRM solution you opt for, remember that its implementation needs to be quick, well planned and relevant to the target customers in order to be effective.

Philadelphia, PA premium rating laws state that each insurance company can calculate their own rates. Therefore, each company's rates can and will differ.

Tags

Links

Top Articles - New Patent Bill; is It Worthy of Its PR?

Related Articles: